Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.60 per 10 shares, totaling RMB 51,852,024.90 (including tax) based on a total share capital of 199,430,865 shares[7]. - The total cash dividends for the year 2024 are expected to reach RMB 154,802,074.70 (including tax) if the proposed distribution plan is approved[8]. - The board of directors has authorized the formulation of a specific mid-term profit distribution plan for 2024[8]. Financial Performance - The company's operating revenue for 2024 reached ¥896,534,453.46, representing a 4.14% increase compared to ¥860,933,244.79 in 2023[24]. - The net profit attributable to shareholders for 2024 was ¥219,327,779.08, a slight increase of 0.11% from ¥219,087,891.18 in 2023[24]. - The net profit after deducting non-recurring gains and losses was ¥215,090,754.66, up 2.85% from ¥209,137,599.61 in 2023[24]. - The net cash flow from operating activities increased by 34.98% to ¥215,293,605.06 in 2024, compared to ¥159,500,018.77 in 2023[24]. - The company's total assets as of the end of 2024 were ¥2,527,540,551.74, reflecting a 14.39% increase from ¥2,209,668,213.23 at the end of 2023[24]. - The net assets attributable to shareholders increased by 18.05% to ¥2,248,637,420.86 at the end of 2024, compared to ¥1,904,838,829.13 at the end of 2023[24]. - The basic earnings per share for 2024 were ¥1.13, a decrease of 3.42% from ¥1.17 in 2023[25]. - The weighted average return on equity decreased to 10.51% in 2024, down from 12.22% in 2023, a reduction of 1.71 percentage points[25]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 7.85% in 2024, up from 6.48% in 2023[25]. - The company invested a total of 70.41 million yuan in R&D, representing a 26.25% increase year-on-year[36]. - The company has established a comprehensive drug development system, covering all stages from compound screening to industrialization, supported by a professional R&D team[68][69]. - The company is actively engaged in the research and development of innovative drugs for conditions such as depression and tumors[38]. - The company is developing a new antidepressant drug JJH201501, which has completed Phase II clinical trials and is currently in Phase III trials, showing significant efficacy and good safety profile[60]. - The anticancer drug JJH201601 has completed Phase I clinical trials and is now in Phase IIa trials, demonstrating superior tumor suppression effects compared to imported docetaxel injections[61]. - The company is developing a new diabetes treatment using mulberry leaf extracts, with quality standards established and ongoing research on extraction and stability[65]. Product Development and Innovation - The company is advancing multiple new drug projects, including JJH201601 and JJH201701, with significant progress reported[35]. - The company has developed multiple deuterated compounds, including new drugs for depression (JJH201501), gastric acid (JJH201701), gallbladder inflammation and gallstones (JJH201801), and diabetes (JJH202301)[97]. - The company has established various research centers and innovation platforms, contributing to its ongoing technical advancements and product development[114]. - The company’s product range includes treatments for various conditions, such as hypertension, immune enhancement, and joint diseases, catering to diverse market needs[111]. Market and Competitive Landscape - The global pharmaceutical market is projected to reach $1,711.4 billion by 2025, with a CAGR of 5.70% from 2020 to 2025, and $2,105.9 billion by 2030, with a CAGR of 4.20% from 2025 to 2030[76]. - China's pharmaceutical market is expected to reach ¥228.73 billion by 2025, with a CAGR of 9.60% from 2020 to 2025, and ¥299.11 billion by 2030[77]. - The pharmaceutical industry is characterized by high technical, financial, and talent requirements, with significant barriers to entry due to long development cycles and high investment costs[82][83]. - The company aims to expand its market presence and sales scale through optimized marketing strategies and new product development[74]. Corporate Governance - The company has confirmed that all directors are present at the board meeting[5]. - The company has not disclosed any special arrangements for corporate governance[10]. - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with corporate governance standards[184]. - The company has established a supervisory board consisting of three supervisors, including one employee representative supervisor, ensuring compliance with relevant laws and regulations[185]. Risk Management - The company has outlined various risks in its operations, which are detailed in the management discussion and analysis section[4]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[11]. - The company is closely monitoring macroeconomic risks and is prepared to implement measures to mitigate potential impacts on business development[126]. - The company faces risks related to the potential imitation of its main products, particularly Licorice tablets, which could impact its exclusive production status[119]. Talent and Human Resources - The company has established a comprehensive talent training system to support its strategic development, ensuring a stable and effective human resource base[37]. - The number of R&D personnel increased to 122, representing 9.19% of the total workforce, up from 7.40% in the previous period[110]. - The total compensation for R&D personnel was 22,040,538.32 RMB, with an average salary of 180,660.15 RMB, a decrease from 198,780.07 RMB in the prior period[110]. - The company emphasizes the importance of retaining core technical personnel, as their expertise is crucial for ongoing innovation and development[122]. Future Outlook - Future outlook indicates a projected revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[193]. - The company plans to enhance its digital marketing efforts, aiming for a 40% increase in online sales channels[192]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market presence[192]. - The company is committed to upgrading production capacity and enhancing digital transformation through new project implementations[181].

前十大流通股东累计持有： 15006.8万股，累计占流通股比： 75.24%，较上期变化： 119.06万股。 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 1.1300 | 1.1700 | -3.42 | 0.8300 | | 每股净资产（元） | 11.28 | 10.07 | 12.02 | 9.03 | | 每股公积金(元) | 6.52 | 5.72 | 13.99 | 5.58 | | 每股未分配利润(元) | 3.26 | 2.85 | 14.39 | 1.98 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 8.97 | 8.61 | 4.18 | 6.55 | | 净利润(亿元) | 2.19 | 2.19 | 0 | 1.55 | | 净资产收益率(%) | 10.51 | 12.22 | -13.99 | 9.36 | 数据四舍五入，查看更多财务数据>> 二、前10 ...

致：江苏吉贝尔药业股份有限公司 北京市金杜（南京）律师事务所（以下简称本所）接受江苏吉贝尔药业股 份有限公司（以下简称公司）委托，根据《中华人民共和国证券法》《中华人 民共和国公司法》、中国证券监督管理委员会（以下简称中国证监会）《上市 公司股东会规则（2025 修订）》（以下简称《股东会规则》）等中华人民共和 国境内（以下简称中国境内，为本法律意见书之目的，不包括中华人民共和国 香港特别行政区、中华人民共和国澳门特别行政区和中华人民共和国台湾地区） 现行有效的法律、行政法规、规章及规范性文件和现行有效的公司章程有关规 定，指派律师出席了公司于 2025 年 4 月 14 日召开的 2025 年第一次临时股东 大会（以下简称本次股东大会），并就本次股东大会相关事项出具本法律意见 书。 北京市金杜（南京）律师事务所 关于江苏吉贝尔药业股份有限公司 2025 年第一次临时股东大会 之法律意见书 在本法律意见书中，本所仅对本次股东大会召集和召开的程序、出席本次 股东大会人员资格和召集人资格及表决程序、表决结果是否符合有关法律、行 政法规、《股东会规则》和《公司章程》的规定发表意见，并不对本次股东大 会所审议的议案内 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-021 江苏吉贝尔药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 4 月 14 日 （二） 股东大会召开的地点：江苏省镇江市高新技术产业开发园区公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 98 | | --- | --- | | 普通股股东人数 | 98 | | 2、出席会议的股东所持有的表决权数量 | 138,000,778 | | 普通股股东所持有表决权数量 | 138,000,778 | | 3、出席会议的股东所持有表决权数量占公司表决权数 | 69.1973% | | 量的比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比 | 69.1973% | | 例（%） ...

Core Viewpoint - Jiangsu Jibeier Pharmaceutical Co., Ltd. has announced the approval and public disclosure of the list of incentive recipients for its 2025 restricted stock incentive plan, ensuring compliance with relevant regulations and internal governance [1][2]. Disclosure Situation - The company disclosed the draft of the 2025 restricted stock incentive plan and its summary on the Shanghai Stock Exchange website on March 29, 2025 [1]. - From March 29 to April 7, 2025, the names and positions of the first batch of incentive recipients were publicly announced internally for a period of 10 days, during which no objections were raised [2]. Verification Opinions - The supervisory board confirmed that the recipients of the incentive plan meet the conditions set forth in the relevant laws, regulations, and the draft plan, excluding supervisors and independent directors from the list [2]. - The recipients possess the necessary qualifications as per the Company Law and the company's articles of association, and do not fall under any disqualifying conditions outlined in the management regulations [2].

江苏吉贝尔药业股份有限公司 监事会关于公司 2025 年限制性股票激励计划首次授 予激励对象名单审核及公示情况的说明 本公司监事会及全体监事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏吉贝尔药业股份有限公司（以下简称"公司"）于 2025 年 3 月 28 日召 开第四届董事会第十四次会议、第四届监事会第十三次会议，审议通过了《公司 2025 年限制性股票激励计划（草案）及摘要》等相关议案。根据《上市公司股 权激励管理办法》（以下简称"《管理办法》"）的相关规定，公司对 2025 年限 制性股票激励计划（以下简称"本次激励计划"）首次授予的激励对象名单在公 司内部进行了公示。公司监事会结合公示情况对首次授予的激励对象名单进行了 核查，相关公示情况及核查情况如下： 一、公示情况 1、公司于 2025 年 3 月 29 日在上海证券交易所网站（www.sse.com.cn）上 披露了《江苏吉贝尔药业股份有限公司 2025 年限制性股票激励计划（草案）》（以 下简称"《激励计划（草案）》"）及摘要、《江苏吉贝尔药业股份有限公司 2025 年限制 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-010 江苏吉贝尔药业股份有限公司 重要内容提示： ● 大股东持有股份的基本情况 南通汇吉科技发展有限公司(以下简称"汇吉科技")持有江苏吉贝尔药业股份有限公司(以下简称"公司") 股份16,320,000股，占公司总股本的8.18%，前述股份来源于公司首次公开发行前持有的股份，已于 2021年5月18日开市起上市流通。 ● 减持计划的实施结果情况 2024年12月20日，公司披露了《江苏吉贝尔药业股份有限公司关于持股5%以上股东减持股份计划公 告》（公告编号：2024-062），汇吉科技计划通过竞价交易方式减持不超过620,000股其所持有的公司 股份，占公司总股本不超过0.31%，减持期间为2025年1月14日至2025年4月11日，减持价格按市场价格 确定。 公司收到股东汇吉科技出具的《股份减持结果告知函》，截至2025年4月3日收市，汇吉科技通过集中竞 价方式累计减持公司股份620,000股，占公司总股本的0.31%。 一、减持主体减持前基本情况 关于持股5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-010 江苏吉贝尔药业股份有限公司 关于持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 大股东持有股份的基本情况 南通汇吉科技发展有限公司(以下简称"汇吉科技")持有江苏吉贝尔药 业股份有限公司(以下简称"公司")股份 16,320,000 股，占公司总股本 的 8.18%，前述股份来源于公司首次公开发行前持有的股份，已于 2021 年 5 月 18 日开市起上市流通。 ? 减持计划的实施结果情况 持股 5%以上股东减持股份计划公告》 （公告编号：2024-062），汇吉科 技计划通过竞价交易方式减持不超过 620,000 股其所持有的公司股份， 占公司总股本不超过 0.31%，减持期间为 2025 年 1 月 14 日至 2025 年 公司收到股东汇吉科技出具的《股份减持结果告知函》，截至 2025 年 4 月 3 日收市，汇吉科技通过集中竞价方式累计减持公司股份 620,000 股， 占公司 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2025-010 | 股东名称 | 南通汇吉科技发展有限公司 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | √是 | □否 | 一、减持主体减持前基本情况 1 大股东持有股份的基本情况 南通汇吉科技发展有限公司(以下简称"汇吉科技")持有江苏吉贝尔药 业股份有限公司(以下简称"公司")股份 16,320,000 股，占公司总股本 的 8.18%，前述股份来源于公司首次公开发行前持有的股份，已于 2021 年 5 月 18 日开市起上市流通。 减持计划的实施结果情况 | | 董事、监事和高级管理人员 | □是 | √否 | | --- | --- | --- | --- | | 持股数量 | 16,320,000 股 | | | | 持股比例 | 8.18% | | | | 当前持股股份来源 | 前取得：16,320,000 股 IPO | | | 上述减持主体无一致行动人。 江苏吉贝尔药业股份有限公司 关于持股 5%以上股东减持股份结 ...

证券代码：688566 证券简称：吉贝尔 江苏吉贝尔药业股份有限公司 2025 年第一次临时股东大会 会议资料 二〇二五年四月 江苏吉贝尔药业股份有限公司 2025 年第一次临时股东大会会议资料 江苏吉贝尔药业股份有限公司 2025 年第一次临时股东大会会议须知 为了维护公司全体股东的合法权益，确保股东大会的正常秩序和议事效 率，保证大会的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证 券法》《上市公司股东大会规则》以及《江苏吉贝尔药业股份有限公司章程》等 相关规定，江苏吉贝尔药业股份有限公司（以下简称"公司"）特制定本次股 东大会会议须知： 一、股东大会设会务组，由公司董事会秘书负责会议的程序安排和会务工 作； 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，务 请出席大会的股东或其代理人及其他出席、列席人员准时到达会场签到确认参 会资格。会议开始后，会议登记应当终止，由会议主持人宣布现场出席会议的 股东和代理人人数及所持有的表决权数量； 三、会议按照会议通知上所列顺序审议、表决议案； 四、股东及股东代理人参加股东大会依法享有发言权、质询权、表决权等 权利。股东及股东代理人参加股东大 ...